VCN Biosciences Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 10

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 2

VCN Biosciences General Information

Description

Developer of pharmaceuticals dedicated to discovering new therapeutic approaches for tumors that lack effective treatment. The company uses an oncolytic adenovirus technology platform to design agents that replicate and self-amplify exclusively in tumor cells, thereby helping healthcare institutes with the treatment of refractory tumors such as pancreatic adenocarcinomas.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Avinguda de la Generalitat, 152
  • Sant Cugat del Vallès
  • 08174 Barcelona
  • Spain
Primary Industry
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Avinguda de la Generalitat, 152
  • Sant Cugat del Vallès
  • 08174 Barcelona
  • Spain

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

VCN Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore VCN Biosciences‘s full profile, request access.

Request a free trial

VCN Biosciences Patents

VCN Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3512533-B9 Oncolytic viral vectors for use in the treatment of retinoblastoma Active 17-Nov-2016
EP-3512533-A1 Use of viral vectors in the treatment of retinoblastoma Active 17-Nov-2016
ES-2827012-T3 Use of viral oncolytic vectors in the treatment of retinoblastoma Active 17-Nov-2016
EP-3512533-B1 Oncolytic viral vectors for use in the treatment of retinoblastoma Active 17-Nov-2016
US-20180153946-A1 Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment Active 04-May-2015 A61K35/761
To view VCN Biosciences’s complete patent history, request access »

VCN Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

VCN Biosciences Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore VCN Biosciences‘s full profile, request access.

Request a free trial

VCN Biosciences FAQs

  • When was VCN Biosciences founded?

    VCN Biosciences was founded in 2009.

  • Where is VCN Biosciences headquartered?

    VCN Biosciences is headquartered in Barcelona, Spain.

  • What is the size of VCN Biosciences?

    VCN Biosciences has 10 total employees.

  • What industry is VCN Biosciences in?

    VCN Biosciences’s primary industry is Drug Discovery.

  • Is VCN Biosciences a private or public company?

    VCN Biosciences is a Private company.

  • What is the current valuation of VCN Biosciences?

    The current valuation of VCN Biosciences is .

  • What is VCN Biosciences’s current revenue?

    The current revenue for VCN Biosciences is .

  • Who are VCN Biosciences’s investors?

    Gri-Cel has invested in VCN Biosciences.

  • When was VCN Biosciences acquired?

    VCN Biosciences was acquired on 10-Mar-2022.

  • Who acquired VCN Biosciences?

    VCN Biosciences was acquired by Theriva Biologics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »